VC005 tablets for people with non-segmental vitiligo
A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo
PHASE2 · Jiangsu vcare pharmaceutical technology co., LTD · NCT07172347
This trial will test VC005 tablets to see if they safely help adults aged 18–70 with non-segmental vitiligo regain skin pigment.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Jiangsu vcare pharmaceutical technology co., LTD (industry) |
| Locations | 1 site (Beijing, Beijng) |
| Trial ID | NCT07172347 on ClinicalTrials.gov |
What this trial studies
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study comparing VC005 tablets to matching placebo in adults with non-segmental vitiligo. Participants aged 18–70 will be randomly assigned to receive VC005 or placebo and followed for efficacy and safety outcomes. Key exclusions include pregnancy or lactation, complete whitening of facial hair in the vitiligo area, known allergy to VC005 ingredients, prior depigmentation treatments, and recent participation in other experimental drug or device trials. The study will monitor skin repigmentation measures and adverse events to characterize both benefit and tolerability.
Who should consider this trial
Good fit: Adults aged 18–70 with non-segmental vitiligo who can give informed consent, are not pregnant or lactating, and have no history of depigmentation treatment or recent experimental drug/device participation.
Not a fit: People who are pregnant or lactating, have complete whitening of facial hair in the affected areas, are allergic to VC005 ingredients, or previously underwent depigmentation treatment are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, VC005 could help restore pigment and improve appearance and quality of life for people with non-segmental vitiligo.
How similar studies have performed: Other oral and topical approaches for vitiligo have shown mixed but sometimes promising results in early-phase trials, so this oral agent has some rationale but is not yet proven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol. * The subject is between 18 and 70 years of age (including borderline values) , regardless of gender. Exclusion Criteria: * Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period. * All hair in the vitiligo area on the face is white. * Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs. * Subjects who have previously received depigmentation treatment. * Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.
Where this trial is running
Beijing, Beijng
- The Peking University People's Hospital — Beijing, Beijng, China (RECRUITING)
Study contacts
- Study coordinator: xiaojuan lai
- Email: lai_xiaojuan@vcarepharmatech.com
- Phone: 15358160458
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Non-segmental Vitiligo